Protagonist Therapeutics Inc Total Liabilities
Protagonist Therapeutics Inc total liabilities. Based on the latest financial reports, Protagonist Therapeutics Inc (PTGX) has total liabilities worth $56.25 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Protagonist Therapeutics Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Protagonist Therapeutics Inc (2014–2024)
Total liabilities of Protagonist Therapeutics Inc from 2014 to 2024. This chart illustrates how Protagonist Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Protagonist Therapeutics Inc to see how much of total assets are deployed in long-term investments.
Protagonist Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Protagonist Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Swatch Group AG Class N
SW:UHRN
|
Switzerland | CHF1.98 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥12.53 Billion |
|
MINTH GRP LTD UNSP.ADR/20
F:M3I0
|
Germany | €17.89 Billion |
|
Raia Drogasil S.A
SA:RADL3
|
Brazil | R$17.83 Billion |
|
Fiberhome Telecommunication Technologies Co Ltd
SHG:600498
|
China | CN¥27.82 Billion |
|
Applied Digital Corporation
NASDAQ:APLD
|
USA | $3.68 Billion |
|
Scout24 AG
XETRA:G24
|
Germany | €1.08 Billion |
|
One Gas Inc
NYSE:OGS
|
USA | $5.30 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down Protagonist Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see PTGX total assets.
Liquidity & Leverage Metrics
Protagonist Therapeutics Inc Total Liabilities Ratios Explained
Protagonist Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Protagonist Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Protagonist Therapeutics Inc (2014–2024)
The table below shows the annual total liabilities of Protagonist Therapeutics Inc from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $69.43 Million | +226.36% |
| 2023-12-31 | $21.27 Million | -34.18% |
| 2022-12-31 | $32.32 Million | -32.21% |
| 2021-12-31 | $47.67 Million | +6.27% |
| 2020-12-31 | $44.86 Million | -40.15% |
| 2019-12-31 | $74.95 Million | +178.05% |
| 2018-12-31 | $26.96 Million | -37.46% |
| 2017-12-31 | $43.10 Million | +569.81% |
| 2016-12-31 | $6.43 Million | +22.59% |
| 2015-12-31 | $5.25 Million | +121.20% |
| 2014-12-31 | $2.37 Million | -- |
About Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical tri… Read more